ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Simple Search Results

Didn't find what you were looking for? Try the Advanced Search »

Search Again »
  • Abstract Number: 0659 • ACR Convergence 2024

    Obinutuzumab Benefits Patients with Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: A Post Hoc Analysis of a Phase II Trial

    Richard Furie1, Jorge A. Ross Terres2, Elsa Martins3, Imran Hassan4, Thomas Schindler3, Jay Garg5, William F. Pendergraft III6, Ana Malvar7 and Brad Rovin8, 1Northwell Health, Manhasset, NY, 2Genentech, Inc,, San Francisco, 3F. Hoffmann-La Roche Ltd, Basel, Switzerland, 4Hoffmann-La Roche Ltd, Mississauga, Canada, 5Genentech, Inc., South San Francisco, CA, 6Genentech, Inc., Chapel Hill, NC, 7Organización Médica de Investigación, Buenos Aires, Argentina, 8The Ohio State University, Columbus, OH

    Background/Purpose: Lupus nephritis (LN) is the most common severe organ-threatening manifestation of systemic lupus erythematosus (SLE). The randomized, placebo-controlled, Phase II NOBILITY trial (NCT02550652) demonstrated…
  • Abstract Number: 2074 • ACR Convergence 2024

    Experience on the Use of Obinutuzumab off Label in Patients with Refractory Idiopathic Inflammatory Myopathy

    Ivana Ilic1 and Galina Marder2, 1Northwell, Brooklyn, NY, 2Donald and Barbara Zucker School of Medicine at Hofstra/ Northwell, Great Neck, NY

    Background/Purpose: Idiopathic inflammatory myopathy (IIM) is a rare multisystem inflammatory condition leading to significant disability. The management of IIM remains challenging. B cell targeting therapies are…
  • Abstract Number: 0784 • ACR Convergence 2023

    Kidney-Related Outcomes and Steroid-Sparing Effects in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of a Phase 2 Trial

    Brad Rovin1, Jorge Ross Terres2, Sophia Giang3, Thomas Schindler4, Armando Turchetta5, Jay Garg2, Richard Furie6, William F. Pendergraft III2 and Ana Malvar7, 1Ohio State University, Columbus, OH, 2Genentech, Inc., South San Francisco, CA, 3Genentech, Inc., San Francisco, CA, 4F. Hoffmann-La Roche Ltd, Basle, Switzerland, 5F. Hoffmann-La Roche Ltd, Basel, Switzerland, 6Northwell Health, Manhasset, NY, 7Hospital Fernandez, Buenos Aires, Argentina

    Background/Purpose: Preservation of long-term kidney function and sustained reduction of glucocorticoid use are major therapeutic goals in lupus nephritis (LN). In the randomized, double-blind, placebo-controlled,…
  • Abstract Number: 1372 • ACR Convergence 2023

    Obinutuzumab Efficacy and Tolerance in Patients with Auto-Immune Diseases Immunized Against Rituximab

    Mathilde Pezot1, Gaetane Nocturne2, Rakiba Belkhir1, Julien Henry1, Stephan Pavy1, Raphaele Seror3, Xavier Mariette4 and Samuel Bitoun5, 1Rheumatology Department, Université Paris-Saclay, INSERM U1184, Hôpital Bicêtre, APHP, FHU CARE, Le Kremlin-Bicêtre, France, 2APHP, Le Kremlin-Bicêtre, France, 3University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, 4Université Paris-Saclay, Le Kremlin-Bicêtre, France, 5CHU Bicêtre APHP, Le Kremlin-Bicêtre, France

    Background/Purpose: Among patients with auto-immune diseases (AID) treated with Rituximab (RTX), anti-drug antibodies (ADAb) leading to inefficacy and infusion reactions (Wincup and al., Ann Rheum…
  • Abstract Number: 1511 • ACR Convergence 2023

    B-Cell Recovery in a Randomized Controlled Trial of B-Cell Depletion with Obinutuzumab for the Treatment of Proliferative Lupus Nephritis

    Ed Vital1, Dario Roccatello2, David Black3, Rhian Jacob-Moffatt4, Cary M. Looney5, Elsa Martins5, Huiyan (Ashley) Mao3, Thomas Schindler6, Himanshi Seghal5, Jay Garg7, Jorge Ross Terres7 and Richard Furie8, 1University of Leeds, Leeds, United Kingdom, 2University of Torino, Torino, Italy, 3Hoffmann-La Roche Ltd, Mississauga, ON, Canada, 4F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom, 5F. Hoffmann-La Roche Ltd, Basel, Switzerland, 6F. Hoffmann-La Roche Ltd, Basle, Switzerland, 7Genentech, Inc., South San Francisco, CA, 8Northwell Health, Manhasset, NY

    Background/Purpose: Patients with LN who received obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, with standard-of-care (MMF) immunosuppression (Phase II NOBILITY; NCT02550652; PMID 34615636) showed…
  • Abstract Number: 0859 • ACR Convergence 2020

    Biomarkers of B-cell Depletion and Response in a Randomized, Controlled Trial of Obinutuzumab for Proliferative Lupus Nephritis

    Ed Vital1, Philippe Remy2, Luis Fernando Quintana Porras3, Laurent Chiche4, Dominique Chauveau5, Richard Furie6, Thomas Schindler7, Jay Garg8, Matthew Cascino8, Zahir Amoura9, Andrea Doria10, Cary Looney8 and Dario Roccatello11, 1University of Leeds; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 2APHP Groupe Hospitalier Henri-Mondor, Creteil, France, 3Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, 4Hôpital Européen, Marseille, France, 5Hôpital Rangueil, Centre Hospitalier Univ de Toulouse, Toulouse, France, 6Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 7F. Hoffmann-La Roche Ltd., Basel, Switzerland, 8Genentech, Inc., South San Francisco, CA, 9Hôpital Pitié-Salpêtrière, Paris, 10University of Padua, Padua, Italy, 11S Giovanni Hospital, Univ of Turin, Turin, Italy

    Background/Purpose: Incomplete B-cell and plasmablast depletion, as measured using highly sensitive flow cytometry (HSFC), is associated with lower response rates following rituximab in SLE [1].…
  • Abstract Number: 0988 • ACR Convergence 2020

    Two-Year Results from a Randomized, Controlled Study of Obinutuzumab for Proliferative Lupus Nephritis

    Richard Furie1, Gustavo Aroca2, Analia Alvarez3, Hilda Fragoso-Loyo4, Elizabeth Zuta Santillan5, Brad Rovin6, Paul Brunetta7, Thomas Schindler8, Imran Hassan9, Matthew Cascino10, Jay Garg10 and Ana Malvar11, 1Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 2Simon Bolivar University y Clinica de la Costa, Barranquilla, Colombia, 3CEMIC, Buenos Aires, Argentina, 4Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 5Instituto de Ginecología y Reproducción, Lima, Peru, 6The Ohio State University, Columbus, 7Genentech, Inc., South San Francisco, 8F. Hoffmann-La Roche Ltd., Basel, Switzerland, 9Hoffmann-La Roche Ltd, Mississauga, Canada, 10Genentech, Inc., South San Francisco, CA, 11Organizacion Medica de Investigacion, Buenos Aires, Argentina

    Background/Purpose: NOBILITY demonstrated improved renal responses and complete B-cell depletion with the humanized type II anti-CD20 monoclonal antibody obinutuzumab (OBI) compared with placebo (PBO) through…
  • Abstract Number: 1836 • ACR Convergence 2020

    Alternative Renal Response Definitions in a Randomized, Controlled Trial of Obinutuzumab for Proliferative Lupus Nephritis

    Zahir Amoura1, Philippe Remy2, Luis Fernando Quintana Porras3, Laurent Chiche4, Dominique Chauveau5, Dario Roccatello6, Richard Furie7, Thomas Schindler8, Jay Garg9, Matthew Cascino9, Brad Rovin10 and Andrea Doria11, 1Hôpital Pitié-Salpêtrière, Paris, 2APHP Groupe Hospitalier Henri-Mondor, Creteil, France, 3Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, 4Hôpital Européen, Marseille, France, 5Hôpital Rangueil, Centre Hospitalier Univ de Toulouse, Toulouse, France, 6S Giovanni Hospital, Univ of Turin, Turin, Italy, 7Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 8F. Hoffmann-La Roche Ltd., Basel, Switzerland, 9Genentech, Inc., South San Francisco, CA, 10The Ohio State University, Columbus, 11University of Padua, Padua, Italy

    Background/Purpose: Obinutuzumab, a type II anti-CD20 mAb, resulted in rapid and complete B-cell depletion and improved renal responses in proliferative lupus nephritis (LN) in the…
  • Abstract Number: 939 • 2019 ACR/ARP Annual Meeting

    A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obinutuzumab or Placebo in Combination with Mycophenolate Mofetil in Patients with Active Class III or IV Lupus Nephritis

    Richard Furie1, Gustavo Aroca 2, Analía Alvarez 3, Hilda Fragoso-Loyo 4, Elizabeth Zuta Santillán 5, Brad Rovin 6, Thomas Schindler 7, Imran Hassan 8, Matthew Cascino 9, Jay P. Garg 10 and Ana Malvar 11, 1Northwell Health, Great Neck, NY, 2Simon Bolivar University y Clinica de la Costa, Barranquilla, Colombia, 3CEMIC, Buenos Aires, Argentina, 4Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, 5Instituto de Ginecología y Reproducción, Lima, Peru, 6The Ohio State University Medical Center, Columbus, OH, 7F. Hoffmann-La Roche AG, Basel, Switzerland, 8Hoffmann-La Roche Ltd, Mississauga, ON, Canada, 9Genentech, Inc., San Fransisco, CA, 10Genentech, Inc., South San Francisco, CA, 11Hospital Fernandez; Organización Maedica de Investigación, Buenos Aires, Argentina

    Background/Purpose: Randomized trials in lupus nephritis (LN) of type I anti-CD20 monoclonal antibodies failed to demonstrate superiority over standard of care alone. NOBILITY (NCT02550652) is…
  • Abstract Number: 1112 • 2015 ACR/ARHP Annual Meeting

    Obinutuzumab Outperforms Rituximab at Inducing B-Cell Cytotoxicity in Vitro through Fc-Mediated Effector Mechanisms in Rheumatoid Arthritis and Systemic Lupus Erythematosus

    Venkat Reddy1, Christian Klein2, David A. Isenberg3, Geraldine Cambridge4, Martin Glennie5, Mark Cragg6 and Maria J. Leandro1, 1Rheumatology, University College London, London, United Kingdom, 2Roche Pharmaceutical Research & Early Development Oncology Discovery & Translational Area, Roche Glycart AG, Schlieren, Switzerland, 3Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, 4Rheumatology, Centre for Rheumatology and Bloomsbury Rheumatology Unit, University College London, London, United Kingdom, 5Antibody and Vaccine group, Southampton University, Southampton, United Kingdom, 6Antibody and Vaccine group, Cancer Sciences Unit, Faculty of Medicine, Southampton University, Southampton, United Kingdom

    Background/Purpose: Obinutuzumab (OBZ, a Type II anti-CD20 monoclonal antibody [mAb] with afucosylated Fc portion and enhanced affinity for Fcγ receptor III) is more efficient than…
Search Again »

Didn't find what you were looking for? Try the Advanced Search »

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology